Eli Lilly's Record Valuation Puts More Weight on the October 29 Report

Eli Lilly's shares reached a record and pushed the company's market value to roughly $1.17 trillion in the source period, slightly above Berkshire Hathaway's reported $1.14 trillion. The comparison is striking, but it does not explain what investors are paying for. The valuation rests on continued growth from Lilly's diabetes and obesity medicines, plus progress across a broader pipeline.

Goldman Sachs raised its price target to $1,413 from $1,371 and kept a Buy rating. The firm expects Lilly to beat third-quarter estimates and raise its outlook, citing stronger Mounjaro growth outside the United States and Zepbound volume supported by the Medicare GLP-1 Bridge program. Bank of America also raised its target, to $1,397 from $1,341.

Those are analyst forecasts, not company results. Lilly is scheduled to report on October 29, and its investor-relations calendar lists the call for 10 a.m. Eastern time. Estimates cited in the source call for revenue of $22.49 billion and earnings of $7.11 a share. With the stock already discounting strong execution, the mix of volume, supply, pricing and guidance may matter more than a narrow earnings beat.

The company also reported positive Phase 3 results for Omvoh in children aged 6 to 17 with moderately to severely active ulcerative colitis. Among 52 patients who responded after 12 weeks of induction treatment, 50% achieved clinical remission at week 52 and 71.2% achieved symptomatic remission. The study was single-arm and open-label, and safety data covered all 63 enrolled patients. Those design limits make the result less definitive than a controlled trial.

Omvoh is approved for adults with moderately to severely active ulcerative colitis and Crohn's disease, but its safety and effectiveness in pediatric patients have not been established. Lilly plans to submit the pediatric data to regulators, so the results represent a possible label expansion, not a current approval.

The October 29 report will determine whether the operating performance is keeping pace with the valuation. Investors should separate three questions: current GLP-1 demand, the durability of supply and margin gains, and the probability that pipeline programs such as pediatric Omvoh become meaningful commercial products.